01932nas a2200229   4500008004100000024000700041245004500048210004500093260001500138300001200153490000700165520133700172653001301509653001401522653001401536653001901550100002501569700001701594700002401611700002701635856004001662       2023                        eng d  a2300aSub Chronic Toxicity Study of Coumacines0 aSub Chronic Toxicity Study of Coumacines  cMarch 2023  a160-1640 v153 a<p class="rtejustify">Coumacine is a brand-new heterocyclic molecular nucleus that was discovered in 2018. In addition to the unique heterocycle known as coumacine, the designer has developed two variants known as coumacine I and II. Coumacine derivatives had been evaluated for their antibacterial effects <em>in vitro</em> against a variety of aerobic and anaerobic bacteria using conventional bacterial strains, using ciprofloxacin and metronidazole as positive controls. The purpose of this research is to look into the relationship between the anticoagulant activity and hepatotoxicity of coumarin and coumacine because the former is a synthetic precursor of the latter and many natural and synthetic coumarins involving warfarin have anticoagulant activity. Thirty male mice were used in this study and exposed to a subchronic dose of 250 or 500 mg/kg of coumacine I or coumacine II. The results of histochemistry showed dramatic changes in hepatocellular morphology that were dose-dependent for both coumacine I and II. Traditionally, higher doses of Coumacine I and II resulted in a significant increase in liver enzymes. Coumacine I or II did no effect on bleeding time. In conclusion, coumacines at subchronic high doses might have hepatotoxic effects through a mechanism that does not affect the coagulation process</p>
10aBleeding10aClotting.10aCoumacine10aHepatotoxicity1 aAl-Shakarchi, Wejdan1 aSaber, Yasir1 aMerkhan, Marwan, M.1 aMustafa, Yasser, Fakri  uhttps://www.phcogj.com/article/1975